𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vitro evaluation of a novel chemotherapeutic agent, adozelesin, in gynecologic-cancer cell lines

✍ Scribed by Hoa N. Nguyen; Bernd-Uwe Sevin; Hervy Averette; James Perras; Randy Hightower; Ronaldo Ramos; Daniel Donato; Mannuel Penalver


Publisher
Springer
Year
1992
Tongue
English
Weight
660 KB
Volume
30
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


A new hamster fibrosarcoma model for in
✍ Benedict, William F. ;Khwaja, Tasneem A. πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 688 KB

## Abstract A hamster fetal cell clone has been developed for in vitro chemotherapeutic studies as well as in an in vivo fibrosarcoma model system. Highly reproducible quantitative in vitro chemotherapeutic data can be obtained with this cell line within 5 days, and as few as 10^2^ cells produce ra

Evaluation of in vitro chemosensitivity
✍ Robert A. Kratzke; Barnett S. Kramer πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 550 KB

The use of well-characterized human lung cancer cell lines has allowed for new opportunities in preclinical and clinical drug evaluation. Development of semiautomated tests of in vitro cytotoxicity such as the MTT assay, which utilizes the formazan salt 3-(4,~-dimethylthiazol-2-yl)-2,S-diphenyltetra

In vitro evaluation of a new nitrosourea
✍ Henrik Roed; Lars L. VindelΓΈv; Mogens Spang-Thomsen; Ib J. Christensen; Heine HΓΈ πŸ“‚ Article πŸ“… 1987 πŸ› Springer 🌐 English βš– 299 KB

The cytotoxic activity of a new nitrosourea, TCNU, was compared with that of BCNU in five human small cell lung cancer cell lines in vitro. TCNU was found to be equivalent or inferior to BCNU when compared on a microgram to microgram basis. If the potential of in vitro phase II trials for selection

In vitro response of human small-cell lu
✍ E. F. Smit; E. G. E. de Vries; H. Timmer-Bosscha; L. F. H. M. de Leij; J. W. Oos πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 French βš– 844 KB

Three cell lines derived from small-cell lung carcinoma (SCLC) tumors of patients who had no clinical response after treatment with a multi-drug regimen were compared to 3 cell lines derived from tumors of patients who, upon treatment, showed a complete clinical response. These 2 groups of cell line